Biomarkers and translational research and precision medicine

50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy

Authors
  • Diederick Keizer (Eindhoven, Netherlands)
  • Marcia A. Inda (Eindhoven, Netherlands)
  • Danielle Clout (Eindhoven, Netherlands)
  • Anja Van de Stolpe (Eindhoven, Netherlands)
  • Anu Fernando (Edinburgh, United Kingdom)
  • Carlos Martinez-Perez (Edinburgh, United Kingdom)
  • J. Michael Dixon (Edinburgh, United Kingdom)
  • Andrew H. Sims (Edinburgh, United Kingdom)
  • Arran K. Turnbull (Edinburgh, United Kingdom)
Speakers
  • Diederick Keizer (Eindhoven, Netherlands)

Previous ePoster
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms

Next ePosters
51P - Higher ER load is not associated with better outcome in stage I-III breast cancer
52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
54P - Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
55P - Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome
58P - Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers
59P - Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients
60P - Anti-inflammatory treatment and inhibition of B-cell activation in a nude mouse model of human breast cancer
61P - Founder mutations BRCA2 c.156_157insAlu in Portuguese population
62P - Growth inhibition of triple-negative breast cancer cells due to the lack of CD73